Actavis Divests In China But Looking For Acquisition; CEO Says Pfizer’s Established Products Division Possible
This article was originally published in PharmAsia News
Actavis is pulling out of China because its business there is too small and complicated considering the investment of time and capital that could be better spent elsewhere But it could re-enter via a sizeable acquisition, such as Pfizer’s Established Products division.
You may also be interested in...
Actavis Realigns Business To Increase Efficiency
The global specialty brand and generics company is simplifying its structure and combining units to make communication and decisions across the business more effective as it strives to grow organically.
Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets? (Part 2 of 2)
[Editor's note: This is part two of a two-part story; part one appeared in PharmAsia News, March 4, 2011.]
Asia Spotlight: Ascendancy Healthcare CEO Sandy Zweifach On The Gap In China
Seeing a gap between the large infrastructure being built in China by multinational and domestic companies, Ascendancy hopes to be an interface to help China access drugs from the West.